JMJolyon P. Mitchell

Jolyon P. Mitchell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jolyon P. Mitchell has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatial aerosol flow maldistribution: A design flaw confounding the proper calibration and data interpretation of stages “0” and “1” of the Andersen eight-stage nonviable cascade impactor

    by Daryl L. Roberts, Jolyon P. Mitchell

    We introduced monodisperse calibrant particles into an eight-stage non-viable Andersen cascade impactor (ACI) operated at 28.3 L/min and separately quantified the particle mass captured under each of the four concentric rings of nozzles on stages 0 and 1, the entry and succeeding stages of this impactor. On both stages, we found that each ring of nozzles has a particle capture efficiency behavior that differs from the others, and the fraction of calibrant particles deposited under each of the individual rings of nozzles depended on the particle size. We believe this behavior derives primarily from a radial flow velocity non-uniformity associated with recirculation zones introduced by the 110° expansion angle of the inlet cone. Because of these recirculation zones, the inertia of particles larger than about 5 µm aerodynamic diameter will cause their point-wise local concentration to differ from the concentration at the inlet entry. This concentration maldistribution continues to stage 1 primarily because of the annular collection plate at stage 0. The influence of the inlet cone aerodynamics on the performance of both stages means that the size of particles deposited on these plates will be uncertain unless the aerosol transport entering the impactor associated with calibration using monodisperse particles exactly simulates the in-use aerosol flow conditions. The degree of realism necessary in the calibration method has heretofore not been discussed in published calibrations of the ACI, introducing uncertainty in the size interpretation of the particle mass collected on stages 0 and 1 in practical applications of this impactor. Copyright © 2017 American Association for Aerosol Research


  • Improved laboratory test methods for orally inhaled products

    by Jolyon P Mitchell, Mark W Nagel

    Existing pharmacopeial methods for the in vitro testing of orally inhaled products (OIPs) are simplified representations of clinical reality, as their objective is to provide metrics that are discriminating of product quality. Attempts to correlate measures such as fine particle fraction <5 µm aerodynamic diameter with in vivo measures of lung deposition have therefore been notoriously difficult to achieve. Although particle imaging-based techniques may be helpful to link in vitro to in vivo data as surrogates for clinical responses, a reappraisal of the purposes for laboratory-based testing of OIPs is required. This article provides guidance on approaches that may be helpful to develop clinically appropriate methods to assess OIP performance in the laboratory, with the ultimate goal of developing robust in vitro–in vivo relationships for the major inhaled drug classes.


  • The Effect of Nonideal Cascade Impactor Stage Collection Efficiency Curves on the Interpretation of the Size of Inhaler-Generated Aerosols

    by D. L. Roberts, J. P. Mitchell

    Cascade impactors, operating on the principle of inertial size separation in (ideally) laminar flow, are used to determine aerodynamic particle size distributions (APSDs) of orally inhaled product (OIP) aerosols because aerodynamic diameter can be related to respiratory tract deposition. Each stage is assumed typically to be an ideal size fractionator. Thus, all particles larger than a certain size are considered collected and all finer particles are treated as penetrating to the next stage (a step function stage efficiency curve). In reality, the collection efficiency of a stage smoothly increases with particle size as an “S-shaped” curve, from approximately 0% to 100%. Consequently, in some cases substantial overlap occurs between neighboring stages. The potential for bias associated with the step-function assumption has been explored, taking full resolution and two-stage abbreviated forms of the Andersen eight-stage nonviable impactor (ACI) and the next-generation pharmaceutical impactor (NGI) as example apparatuses. The behavior of unimodal, log-normal APSDs typical of OIP-generated aerosols has been investigated, comparing known input values to calculated values of central tendency (mass median aerodynamic diameter) and spread (geometric standard deviation, GSD). These calculations show that the error introduced by the step change assumption is larger for the ACI than for the NGI. However, the error is sufficiently small to be inconsequential unless the APSD in nearly monodisperse (GSD ≤1.2), a condition that is unlikely to occur with realistic OIPs. Account may need to be taken of this source of bias only for the most accurate work with abbreviated ACI systems.


  • Good Cascade Impactor Practice (GCIP) and Considerations for “In-Use” Specifications

    by S. C. Nichols, J. P. Mitchell, C. M. Shelton, D. L. Roberts

    The multi-stage cascade impactor (CI) is widely used to determine aerodynamic particle size distributions (APSDs) of orally inhaled products. Its size-fractionating capability depends primarily on the size of nozzles of each stage. Good Cascade Impactor Practice (GCIP) requires that these critical dimensions are linked to the accuracy of the APSD measurement based on the aerodynamic diameter size scale. Effective diameter (D eff) is the critical dimension describing any nozzle array, as it is directly related to stage cut-point size (d 50). d 50 can in turn be determined by calibration using particles of known aerodynamic diameter, providing traceability to the international length standard. Movements in D eff within manufacturer tolerances for compendial CIs result in the worst case in shifts in d 50 of <±10%. Stage mensuration therefore provides satisfactory control of measurement accuracy. The accurate relationship of D eff to d 50 requires the CI system to be leak-free, which can be checked by sealing the apparatus at the entry to the induction port and isolating it from the vacuum source and measuring the rate of pressure rise before each use. Mensuration takes place on an infrequent basis compared with the typical interval between individual APSD determinations. Measurement of stage flow resistance (pressure drop; ΔP stage) could enable the user to know that the CI stages are fit for use before every APSD measurement, by yielding an accurate measure of D eff. However, more data are needed to assess the effects of wear and blockage before this approach can be advocated as part of GCIP.


  • Adapting the Abbreviated Impactor Measurement (AIM) Concept to Make Appropriate Inhaler Aerosol Measurements to Compare with Clinical Data: A Scoping Study with the “Alberta” Idealized Throat (AIT) Inlet

    by Jolyon Mitchell, Mark Copley, Yvonne Sizer, Theresa Russell, Derek Solomon

    Background: The Abbreviated Impactor Measurement (AIM) concept simplifies determination of aerodynamic size metrics for inhaler quality control testing. A similar approach is needed to compare in vitro particle size distribution metrics with human respiratory tract (HRT) deposition. Methods: An abbreviated impactor based on the Andersen eight-stage cascade impactor (ACI) was developed having two size-fractionating stages with cut-points at 4.7 and 1.1 μm aerodynamic diameter at 28.3 L/min, to distinguish between coarse (CPM), fine (FPM), and extra-fine (EPM) mass fractions likely to deposit in the oropharynx, airways of the lungs, or be exhaled, respectively. In vitro data were determined for pressurized metered dose inhaler (pMDI)-delivered salbutamol (100 μg/actuation ex valve) with an “Alberta” idealized adult upper airway (throat) inlet (AIM-pHRT). Corresponding benchmark data for a full resolution Andersen eight-stage cascade impactor with “Alberta” idealized throat (ACI-AIT) and ACI-Ph.Eur./USP inlet were obtained with the same product. Results: Mass recoveries (μg/actuation; mean±SD) were equivalent at 100.5±0.7; 97.2±4.9 and 101.5±9.5 for the AIM-pHRT, ACI-AIT, and ACI-Ph.Eur./USP induction port, respectively [one-way analysis of variance (ANOVA), p=0.64]. Corresponding values of CPM were 59.2±4.2; 58.4±2.4, and 65.6±5.8; the AIT captured larger particles more efficiently than the Ph.Eur./USP induction port, so that less large particle mass was apparent in the upper stages of the ACI-AIT (p≤0.037). Equivalent values of FPM were similar regardless of inlet/abbreviation at 41.3±4.2; 38.7±3.0, and 35.9±3.8 (p=0.054), and EPM measures (1.7±0.3; 2.0±0.5; 2.1±0.3) were also comparable (p=0.32). Conclusions: The AIT inlet significantly increased the capture of the coarse fraction compared with that collected by the Ph.Eur./USP induction port. Measures obtained using the AIM-pHRT apparatus were comparable with those obtained with the ACI-AIT.


  • Effect of Sampling Volume on Dry Powder Inhaler (DPI)-Emitted Aerosol Aerodynamic Particle Size Distributions (APSDs) Measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen Eight-Stage Cascade Impactor (ACI)

    by Hlack Mohammed, Daryl L. Roberts, Mark Copley, Mark Hammond, Steven C. Nichols, Jolyon P. Mitchell

    Current pharmacopeial methods for testing dry powder inhalers (DPIs) require that 4.0 L be drawn through the inhaler to quantify aerodynamic particle size distribution of “inhaled” particles. This volume comfortably exceeds the internal dead volume of the Andersen eight-stage cascade impactor (ACI) and Next Generation pharmaceutical Impactor (NGI) as designated multistage cascade impactors. Two DPIs, the second (DPI-B) having similar resistance than the first (DPI-A) were used to evaluate ACI and NGI performance at 60 L/min following the methodology described in the European and United States Pharmacopeias. At sampling times ≥2 s (equivalent to volumes ≥2.0 L), both impactors provided consistent measures of therapeutically important fine particle mass (FPM) from both DPIs, independent of sample duration. At shorter sample times, FPM decreased substantially with the NGI, indicative of incomplete aerosol bolus transfer through the system whose dead space was 2.025 L. However, the ACI provided consistent measures of both variables across the range of sampled volumes evaluated, even when this volume was less than 50% of its internal dead space of 1.155 L. Such behavior may be indicative of maldistribution of the flow profile from the relatively narrow exit of the induction port to the uppermost stage of the impactor at start-up. An explanation of the ACI anomalous behavior from first principles requires resolution of the rapidly changing unsteady flow and pressure conditions at start up, and is the subject of ongoing research by the European Pharmaceutical Aerosol Group. Meanwhile, these experimental findings are provided to advocate a prudent approach by retaining the current pharmacopeial methodology.